Genfit S.A. (GNFTF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genfit S.A. (GNFTF) with AI Score 73/100 (Buy). Genfit S. A. is a biopharmaceutical company focused on discovering and developing treatments for metabolic and liver diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Genfit S.A. (GNFTF) Healthcare & Pipeline Overview
Genfit S.A. is a biopharmaceutical company specializing in metabolic and liver disease treatments, including Elafibranor for primary biliary cholangitis. With diagnostic solutions like NIS4 technology and partnerships with Labcorp and Genoscience Pharma, Genfit navigates the competitive biotech landscape, focusing on unmet needs in liver-related conditions.
Investment Thesis
Genfit S.A. presents a focused investment opportunity within the biotechnology sector, driven by its pipeline of drug candidates targeting liver diseases. The Phase 3 clinical trial of Elafibranor for PBC represents a near-term catalyst, with potential for market approval and revenue generation. The development of NIS4 technology for NASH diagnosis offers a longer-term growth avenue, addressing the increasing prevalence of NASH globally. However, the company's negative profit margin of -85.9% and reliance on clinical trial outcomes pose significant risks. Successful commercialization of its products and strategic partnerships are crucial for achieving profitability and shareholder value. Investors should closely monitor clinical trial results, regulatory approvals, and competitive dynamics within the liver disease treatment market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.54 billion reflects investor valuation of Genfit's pipeline and potential.
- A P/E ratio of -11.22 indicates that the company is currently unprofitable, typical for biotechnology firms in the development stage.
- Gross margin of 93.1% suggests strong potential profitability upon successful commercialization of its products.
- Beta of 1.19 indicates that the stock is slightly more volatile than the market, reflecting the inherent risks in biotechnology investments.
- The company's focus on liver diseases addresses a significant unmet medical need, driving potential for future growth.
Competitors & Peers
Strengths
- Proprietary drug candidates in clinical development.
- Strong expertise in metabolic and liver diseases.
- Strategic partnerships with leading companies.
- Innovative diagnostic technologies.
Weaknesses
- High reliance on clinical trial outcomes.
- Negative profitability.
- Limited commercial infrastructure.
- Dependence on partnerships for commercialization.
Catalysts
- Upcoming: Results from Phase 3 clinical trial of Elafibranor for PBC expected in late 2026 or early 2027.
- Ongoing: Commercialization of NASHnext through partnership with Labcorp.
- Upcoming: Potential regulatory approval of Elafibranor for PBC in late 2027, if Phase 3 results are positive.
- Ongoing: Development of NIS4 technology for NASH diagnosis.
- Upcoming: Advancement of GNS561 through Phase 1b/2 trial for CCA with potential data release in 2027.
Risks
- Potential: Failure of Elafibranor in Phase 3 clinical trials.
- Potential: Regulatory hurdles in obtaining approval for Elafibranor.
- Ongoing: Competition from other companies developing treatments for liver diseases.
- Ongoing: Dependence on partnerships for commercialization.
- Potential: Patent expiration on key technologies.
Growth Opportunities
- Elafibranor for Primary Biliary Cholangitis (PBC): Elafibranor, currently in Phase 3 clinical trials, represents a significant growth opportunity for Genfit. If approved, Elafibranor could address a substantial unmet need in the treatment of PBC, a chronic liver disease. The PBC market is projected to grow, driven by increased awareness and improved diagnostic methods. Successful completion of Phase 3 trials and subsequent regulatory approval could lead to significant revenue generation for Genfit, potentially starting in late 2026 or early 2027.
- NIS4 Technology for NASH Diagnosis: The development of NIS4 technology for the non-invasive diagnosis of NASH and fibrosis offers a compelling growth avenue. NASH is a rapidly growing liver disease, and early diagnosis is crucial for effective management. NIS4 aims to provide a convenient and accurate diagnostic tool, potentially capturing a significant share of the NASH diagnostics market. Commercialization of NIS4, potentially through partnerships, could contribute to Genfit's revenue growth starting in 2027.
- GNS561 for Cholangiocarcinoma (CCA): Genfit's GNS561, currently in Phase 1b/2 trial for CCA, represents a longer-term growth opportunity. CCA is a rare but aggressive cancer of the bile ducts, with limited treatment options. Successful development and commercialization of GNS561 could address a critical unmet need and generate revenue for Genfit, although this is likely several years away, potentially 2029 or later.
- Partnership with Labcorp for NASHnext: Genfit's licensing agreement with Labcorp for the commercialization of NASHnext provides a revenue stream and market access. NASHnext is a blood-based molecular diagnostic test for NASH. This partnership allows Genfit to leverage Labcorp's extensive network and expertise in diagnostics, accelerating the adoption of NASHnext and contributing to Genfit's financial performance. Revenue from this partnership is ongoing.
- Expansion into New Therapeutic Areas: Genfit could explore expansion into new therapeutic areas within metabolic and liver diseases, leveraging its expertise and infrastructure. This could involve developing new drug candidates or acquiring existing assets. Expanding the pipeline would diversify Genfit's revenue streams and reduce its reliance on individual products. This is a longer-term strategy, potentially unfolding over the next 5-10 years.
Opportunities
- Growing market for NASH treatments and diagnostics.
- Expansion into new therapeutic areas.
- Potential for regulatory approval of Elafibranor.
- Increased adoption of NIS4 technology.
Threats
- Competition from other pharmaceutical and biotechnology companies.
- Clinical trial failures.
- Regulatory hurdles.
- Patent expiration.
Competitive Advantages
- Proprietary drug candidates and diagnostic technologies protected by patents.
- Expertise in metabolic and liver diseases.
- Established partnerships with leading pharmaceutical and diagnostic companies.
- Clinical trial data demonstrating the efficacy and safety of its products.
About GNFTF
Genfit S.A., established in 1999 and headquartered in Loos, France, is a biopharmaceutical company dedicated to discovering and developing innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases. The company's primary focus is on addressing significant unmet medical needs in areas such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and cholangiocarcinoma (CCA). Genfit's lead product candidate, Elafibranor, is currently in Phase 3 clinical development for the treatment of PBC. Additionally, the company is developing NIS4 technology for the diagnosis of NASH and fibrosis, aiming to provide a non-invasive diagnostic tool for early detection and monitoring of disease progression. Genfit is also advancing GNS561, a drug candidate in Phase 1b/2 trial for CCA, and Nitazoxanide, in Phase 1 trial for acute-on-chronic liver failure. Genfit has established strategic collaborations, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test, and with Genoscience Pharma for the development and commercialization of GNS561 for CCA. These partnerships underscore Genfit's commitment to expanding its reach and impact in the field of liver diseases.
What They Do
- Discovers and develops drug candidates for metabolic diseases.
- Focuses on treatments for liver-related diseases.
- Develops diagnostic solutions for liver conditions.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval for its products from health authorities.
- Commercializes its products through partnerships and direct sales.
Business Model
- Develops and patents novel drug candidates and diagnostic technologies.
- Out-licenses or partners with other companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
- Potentially generates revenue through direct sales of diagnostic products.
Industry Context
Genfit S.A. operates within the competitive biotechnology industry, focusing on the development of treatments and diagnostics for liver diseases. The NASH market, in particular, is experiencing significant growth due to the increasing prevalence of obesity and related metabolic disorders. Key competitors include BRIBF, BXPHF, IPHYF, JWCTF, and MLLCF, each pursuing different approaches to address liver diseases. Genfit's strategic partnerships and focus on innovative diagnostic solutions position it to capture a share of this expanding market, estimated to reach billions of dollars in the coming years.
Key Customers
- Patients suffering from metabolic and liver diseases.
- Physicians who treat patients with these conditions.
- Diagnostic laboratories that use Genfit's diagnostic products.
- Pharmaceutical companies that partner with Genfit for drug development and commercialization.
Financials
Chart & Info
Genfit S.A. (GNFTF) stock price: Price data unavailable
Latest News
-
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
Yahoo! Finance: GNFTF News · Mar 9, 2026
-
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
Yahoo! Finance: GNFTF News · Feb 26, 2026
-
Stocks That Hit 52-Week Lows Of Monday
· Oct 7, 2019
-
Stocks That Hit 52-Week Lows On Tuesday
· Oct 1, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNFTF.
Price Targets
Wall Street price target analysis for GNFTF.
MoonshotScore
What does this score mean?
The MoonshotScore rates GNFTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
Stocks That Hit 52-Week Lows Of Monday
Stocks That Hit 52-Week Lows On Tuesday
Leadership: Pascal Prigent
Chief Executive Officer
Pascal Prigent serves as the Chief Executive Officer of Genfit S.A., bringing extensive experience in the pharmaceutical and biotechnology industries. His career spans various leadership roles, including positions in sales, marketing, and business development. He has a proven track record of driving growth and innovation in the healthcare sector. Prigent's expertise encompasses strategic planning, product development, and commercialization, making him well-suited to lead Genfit in its mission to develop treatments for metabolic and liver diseases. His leadership is focused on advancing the company's pipeline and expanding its market presence.
Track Record: Under Pascal Prigent's leadership, Genfit has focused on advancing its clinical pipeline, particularly Elafibranor for PBC. He has overseen strategic partnerships aimed at expanding the company's reach and commercial capabilities. Key milestones include the progression of Elafibranor through Phase 3 clinical trials and the development of innovative diagnostic solutions. Prigent's tenure has been marked by a commitment to addressing unmet medical needs in liver diseases and driving shareholder value.
GNFTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Genfit S.A. (GNFTF) may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, potentially increasing investment risk. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in less transparency for investors. This tier is often associated with speculative investments and requires careful due diligence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- The OTC Other tier carries a higher risk of fraud or mismanagement.
- Fewer regulatory requirements provide less investor protection.
- Potential for delisting or suspension of trading.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags, such as pending lawsuits or regulatory investigations.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- The company has a well-defined business model and a clear focus on liver diseases.
- Genfit has established partnerships with reputable companies like Labcorp and Genoscience Pharma.
- The company's lead product candidate, Elafibranor, is in Phase 3 clinical trials.
- Genfit has a team of experienced scientists and executives.
- The company has a history of innovation in the field of liver diseases.
Genfit S.A. Stock: Key Questions Answered
What does Genfit S.A. do?
Genfit S.A. is a biopharmaceutical company focused on developing treatments and diagnostic solutions for metabolic and liver-related diseases. Their lead product candidate, Elafibranor, is in Phase 3 clinical trials for primary biliary cholangitis (PBC). The company also develops NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Genfit partners with companies like Labcorp to commercialize diagnostic tests, aiming to address unmet needs in the diagnosis and treatment of liver diseases.
What do analysts say about GNFTF stock?
AI analysis is pending for GNFTF stock. Generally, biotechnology stocks are evaluated based on their clinical pipeline, potential market size for their drugs, and financial runway. Investors should monitor clinical trial results, regulatory milestones, and competitive dynamics. Valuation metrics often include discounted cash flow analysis, considering the potential revenue from successful drug commercialization. Due to the OTC listing, analyst coverage may be limited, requiring investors to conduct thorough independent research.
What are the main risks for GNFTF?
The primary risks for Genfit S.A. include the potential failure of Elafibranor in Phase 3 clinical trials, which would significantly impact the company's value. Regulatory hurdles in obtaining approval for Elafibranor also pose a risk. Competition from other companies developing treatments for liver diseases, such as NASH and PBC, is an ongoing challenge. The company's reliance on partnerships for commercialization and potential patent expiration on key technologies represent additional risks. Furthermore, the OTC listing introduces liquidity and transparency concerns.
How does Genfit S.A. manage patent expiration risks?
Genfit S.A. manages patent expiration risks through a multi-faceted approach. This includes continuously innovating to develop new drug candidates and diagnostic technologies, extending patent protection through formulation and process patents, and strategically licensing intellectual property. The company also focuses on building a strong portfolio of patents around its core technologies to create barriers to entry for competitors. Furthermore, Genfit actively monitors the competitive landscape and takes legal action when necessary to protect its intellectual property rights.
What is Genfit S.A.'s drug pipeline status?
Genfit S.A.'s drug pipeline includes Elafibranor, currently in Phase 3 clinical trials for primary biliary cholangitis (PBC). GNS561 is in Phase 1b/2 trial for cholangiocarcinoma (CCA), and Nitazoxanide is in Phase 1 trial for acute-on-chronic liver failure. The pipeline also includes NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Key therapeutic areas include PBC, NASH, CCA, and acute-on-chronic liver failure. Upcoming catalysts include the results from the Phase 3 trial of Elafibranor and the advancement of GNS561 through clinical trials.
What are the key factors to evaluate for GNFTF?
Genfit S.A. (GNFTF) currently holds an AI score of 73/100, indicating high score. Key strength: Proprietary drug candidates in clinical development.. Primary risk to monitor: Potential: Failure of Elafibranor in Phase 3 clinical trials.. This is not financial advice.
How frequently does GNFTF data refresh on this page?
GNFTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNFTF's recent stock price performance?
Recent price movement in Genfit S.A. (GNFTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary drug candidates in clinical development.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.
- OTC market data may be less reliable than exchange-listed data.